OpSens and Haemonetics enter into acquisition agreement


OpSens has entered into a definitive arrangement agreement with Haemonetics Corporation that will see Haemonetics indirectly acquire all of the issued and outstanding common shares in the capital of OpSens.

OpSens’ board of directors unanimously approved the transaction and has recommended that shareholders vote in favour of the deal.

OpSens’ products include the OptoWire, a guidewire designed to help in the diagnosis and treatment of fractional flow reserve (FFR), and SavvyWire, a minimalist approach guidewire for transcatheter valve implantation (TAVI) procedures.

Haemonetics believes that these products will provide significant synergies with its own device portfolio, which includes Vascade and Vascade MVP, catheter-based vascular access site closure devices generally used in interventional cardiology, electrophysiology, and peripheral vascular procedures.

“This Transaction will create value for our shareholders and is a testament to the quality of the team’s work over the years, the added value of our products, and the potential for the years to come,” said Louis Laflamme, president and chief executive officer of OpSens. “The integration within Haemonetics should enhance the benefits for OpSens’ products with access to a world-class sales network, while capitalising on the specialised production and R&D expertise of OpSens. From design to production, OpSens’ expertise and knowledge are recognised by clinicians, hospitals and device industry suppliers and OpSens’ innovative products will be a valuable addition to Haemonetics’ existing product line.”

“With the acquisition of OpSens, we expand our leadership in interventional cardiology and strengthen our foundation for additional growth and diversification,” said Stew Strong, president, Global Hospital business unit at Haemonetics “By leveraging OpSens’ proprietary optical sensor technology, our global commercial infrastructure, and our relationships with the top US hospitals performing TAVI and percutaneous coronary intervention (PCI) procedures, we have a powerful opportunity to improve standards of care for more physicians and patients worldwide. We are excited to welcome OpSens’ talented team and look forward to advancing our shared commitment to maximising patient benefits and value for our customers.”


Please enter your comment!
Please enter your name here